ABION's New Drug Shows Promise Against Resistant Cancers

SEOUL, South Korea – April 07, 2026 – South Korean biotechnology firm ABION has announced promising preclinical results for its next-generation cancer therapy, ABN202, which demonstrated a superior ability to fight tumors compared to a leading class of cancer drugs. The findings suggest a potential new weapon against solid tumors that have developed resistance to current treatments.

The data, scheduled for a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in San Diego, indicates that ABN202 could overcome the limitations of TROP2-targeting antibody-drug conjugates (ADCs), a cornerstone of modern oncology.

The Growing Challenge of ADC Resistance

Antibody-drug conjugates have been hailed as “magic bullets” in oncology. They combine the precision of a monoclonal antibody, which seeks out a specific protein on the surface of cancer cells, with a potent cytotoxic payload designed to kill the tumor from within. One of the most important targets for this approach is TROP2, a protein found in high levels on various solid tumors, including certain types of breast, lung, and pancreatic cancers.

Drugs like Sacituzumab Govitecan (Trodelvy) and Datopotamab Deruxtecan (Dato-DXd) have significantly improved outcomes for patients by targeting TROP2. However, their long-term effectiveness is often hampered by a formidable obstacle: drug resistance. Cancers are notoriously adaptable, and tumors can evolve to evade these sophisticated therapies.

Resistance can manifest in several ways. The tumor cells might reduce the amount of TROP2 on their surface, leaving the antibody with nothing to bind to. They can develop mutations in the drug's cellular target or activate molecular pumps that eject the toxic payload before it can do its job. This acquired resistance often leaves patients with few effective treatment options, creating a critical unmet medical need.

A Dual-Action Immuno-Oncology Strategy

ABION's ABN202 represents a fundamentally different approach. Developed on the company's proprietary iRAC (Interferon-β Antibody Conjugate) platform, ABN202 is not a traditional ADC. Instead of carrying a chemical toxin, it fuses a TROP2-targeting antibody directly to Interferon-beta (IFN-β), a powerful, naturally occurring cytokine.

This design gives ABN202 a dual mechanism of action. First, IFN-β itself has direct anti-tumor properties, capable of slowing cancer cell growth and inducing cell death. By attaching it to an antibody, the iRAC platform aims to concentrate this potent molecule directly at the tumor site, maximizing its effect while potentially minimizing the systemic side effects that have limited the use of cytokines in the past.

Second, and perhaps more significantly, IFN-β is a powerful modulator of the immune system. The preclinical data from ABION suggests that ABN202 triggers a robust and sustained immune response against the cancer. It was shown to induce systemic, long-lasting activity from CD8-positive T cells—the “killer” cells of the immune system—which are critical for durable anti-tumor immunity. This suggests that ABN202 doesn't just kill cancer cells directly; it teaches the patient's own immune system to recognize and destroy the tumor.

Outperforming the Competition in Preclinical Models

The strength of this novel approach was highlighted in ABION's preclinical studies. According to the company's announcement, ABN202 not only worked in models that were resistant to conventional TROP2-targeting ADCs, but it also demonstrated superior anti-tumor efficacy compared to a combination of an ADC and an anti-PD-1 immune checkpoint inhibitor.

Checkpoint inhibitors, which work by “releasing the brakes” on the immune system, are a standard pillar of immuno-oncology. The finding that ABN202 alone could outperform a combination of two powerful drug classes underscores its potential as a transformative therapy. By activating a different set of immune pathways via IFN-β, ABN202 may offer a new strategy for patients who do not respond to or have relapsed after treatment with existing ADCs and immunotherapies.

“These results highlight the potential of a differentiated IFN-β-based immuno-oncology strategy to overcome resistance to current ADC therapies,” said Dr. Young Kee Shin, CEO and CTO of ABION, in a statement.

A Platform for the Future and a Hunt for Partners

For ABION, a precision oncology developer listed on South Korea's KOSDAQ exchange, ABN202 is more than just a single drug candidate; it is the flagship product of its versatile iRAC platform. The company emphasizes that the IFN-β fusion technology is not limited to targeting TROP2 and can be adapted to a wide range of antibodies against other solid tumor targets. This platform-based approach provides a clear path for pipeline expansion and future drug development.

While the company also has other candidates in its pipeline, including a cMET inhibitor for lung cancer (ABN401), the focus is squarely on advancing its novel immuno-oncology asset. The next major step for ABN202 is to move from the laboratory to human trials. ABION has stated its intention to file an Investigational New Drug (IND) application with regulatory authorities in the first half of 2027.

Navigating the costly and complex path of clinical development is a significant undertaking for any biotechnology firm. Recognizing this, ABION is actively seeking collaborators. Dr. Shin confirmed the company is “actively exploring strategic partnership opportunities for ABN202, including collaborations at the preclinical stage.” Such a partnership with a larger pharmaceutical firm could provide the necessary capital and global expertise to accelerate ABN202's development, potentially bringing this promising new therapy to patients who have run out of options. The upcoming presentation at AACR 2026 will be a critical showcase as the company looks to attract that strategic interest.